Carcinoid Tumors, Intestinal Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook

Published August 18, 2026 · Evidence accessed through Patsnap Life Sciences MCP servers.

This report evaluates one indication only: Carcinoid Tumors, Intestinal. It connects disease background, epidemiology, a target-mechanism anchor, clinical competition, transaction activity, unmet need and market attractiveness for portfolio and business-development decisions.

Executive assessment

Carcinoid Tumors, Intestinal receives a directional strategic score of 68/100. The synthesis combines unmet need (82/100), competitive intensity (62/100, where a higher value means more competition) and market attractiveness (73/100). It is an evidence-organizing framework, not a revenue forecast or medical recommendation.

Disease background and strategic definition

A well-differentiated, low-grade neuroendocrine neoplasm that arises from the small or large intestine. The mitotic count is less than 2 per 2 mm2 and the Ki-67 index is less than 3%.

The reproducible entity is Patsnap disease ID 5ca8501df39e485cbd3d43e842582500 with MeSH identifier C562842. Entity-level identifiers matter because rare disorders often carry historical names, gene-defined subtypes and overlapping clinical labels. Strategy teams should lock the intended label and synonym set before comparing epidemiology, trials and deals.

A useful target product profile must specify the treatable phenotype, age and severity range, diagnostic confirmation, prior-therapy requirements, treatment setting, acceptable safety profile and endpoint. In Carcinoid Tumors, Intestinal, an overly broad label can inflate the theoretical market while diluting biological signal and making recruitment less predictable.

The care pathway should be mapped from symptom recognition through specialist referral, molecular or biochemical confirmation, treatment initiation and longitudinal monitoring. Diagnostic delay, fragmented referral and limited centers may be as important commercially as drug efficacy. These barriers should appear explicitly in launch and evidence-generation plans.

Epidemiology and disease burden

Epidemiology signal 1: 中国结直肠癌流行现况及2000—2019年趋势变化 Incidence, mortality and trends of colorectal cancer in China from 2000 to 2019

【关键词】 结直肠肿瘤； 发病率； 死亡率； 趋势； 中国 基金项目：首都卫生发展科研专项（2024-2G-40214）；中国医学科学院与健康科技创新工程 （2021-I2M-1-023） Incidence, mortality and trends of colorectal cancer in China from 2000 to 2019 Li Li 1, Zheng Rongshou 1, Wang Shaoming 1, Han Bingfeng 1, Zeng Hongmei 1, Sun Kexin 1, Chen Ru 1, Liu Meicen 1, Wei Wenqiang 2 1 Office for Cancer Registry, National Cancer Center/National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China; 2Office for Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, DOI：10.3760/cma.j.cn112152-20250903-00443 收稿日期 2025-09-03 本文编辑 苏在明 引用本文：李荔, 郑荣寿, 王少明, 等. 中国结直肠癌流行现况及2000—2019 年趋势变化[J]. 中华肿瘤杂 志, 2026, 48(1): 130-136. DOI: 10.3760/cma.j.cn112152-20250903-00443. Beijing 100021, China Corresponding author: Wei Wenqiang, Email: weiwq@cicams.ac.cn

Review the underlying epidemiology source

Epidemiology signal 2: The Burden of Esophageal Cancer in Five East Asian Countries From 1990 to 2021 and Its Prediction Until 2036: An Analysis of the Global Burden of Diseases Study 2021

20. Y. Chen, T. Chen, and J. Y. Fang, “Burden of Gastrointestinal Can- cers in China From 1990 to 2019 and Projection Through 2029,” Cancer Letters 560 (2023): 216127. 21. P. Danpanichkul, K. Suparan, P. Tothanarungroj, et al., “Epidemiol- ogy of Gastrointestinal Cancers: A Systematic Analysis From the Global 37. Y. Liu, H. Yang, J. Xiong, et al., “Icariin as an Emerging Candidate Drug for Anticancer Treatment: Current Status and Perspective,” Bio- medicine & Pharmacotherapy 157 (2023): 113991.

Review the underlying epidemiology source

Epidemiology signal 3: 辽宁省城市地区2006—2022年结直肠癌发病趋势及年龄变化特征 The incidence trend and age change characteristics of colorectal cancer among urban residents in Liaoning Province from 2006 to 2022

地区结直肠癌发病率呈上升趋势，粗发病率由 33.17/10 万上升至67.43/10 万，AAPC 为4.34%（P＜ 0.001）。男性和女性粗发病率均呈上升趋势，AAPC 分 别为5.10%（P＜0.001）和3.38%（P＜0.001）。年龄 标化后，总体和男性发病率仍呈上升趋势（P＜ 0.05），女性发病率变化则无统计学意义（表1）。 3. 年龄别发病率变化趋势：辽宁省城市地区 0～34 岁、35～44 岁年龄组结直肠癌发病率相对较 低，发病率随着年龄的增长而升高（图1）。2006— 2022年，55～64岁、65～74岁、75+岁组居民结直肠 癌发病率呈上升趋势（均P＜0.05），尤其是55～ 64 岁组增幅最大（AAPC=3.79%），男性增幅 （AAPC=4.68%，P＜0.001）高于女性（AAPC=2.07%， P=0.015）。另外，45～54岁组男性结直肠癌发病率 也呈上升趋势（AAPC=1.86%，P=0.003；表2）。 4. 平均发病年龄变化特征：2006—2022 年辽 宁省城市地区结直肠癌平均发病年龄呈增长趋势， 总体平均发病年龄由64.79岁增长至67.24岁，年均 上升0.14 岁（P＜0.001）。男性结直肠癌平均发病 年龄年均上升0.08 岁（P＜0.001），女性年均上升 0.22 岁（P＜0.001）。标化后，总体及不同性别平均 发病年龄变化均无统计学意义（表3）。 5. 中标年龄别发病构成比：与2006 年相比， 2022 年辽宁省城市地区结直肠中标年龄别发病构 表1 辽宁省城市地区2006—2022年结直肠癌发病率变化趋势（1/10万） 注：AAPC为平均年度变化百分比；中标率采用2000年中国人口构成计算；世标率采用Segi's世界人口构成计算

Review the underlying epidemiology source

Epidemiology should be converted into an addressable-patient funnel: total affected population → diagnosed patients → clinically eligible segment → treated patients → realistically accessible patients. Incidence, point prevalence and lifetime prevalence are not interchangeable; estimates from different age bands, case definitions or health systems should not be pooled without adjustment.

For Carcinoid Tumors, Intestinal, the next population work should quantify diagnostic yield, severity distribution, referral-center concentration, treatment penetration and survival or progression. Sensitivity analyses should show how each assumption affects recruitment, peak penetration and budget impact. A transparent range is more useful than a single precise-looking estimate built from incompatible sources.

Unmet need and patient-value thesis

The unmet-need thesis must name the failure that a new intervention will change: irreversible progression, incomplete disease control, treatment-limiting toxicity, burdensome administration, weak durability, delayed diagnosis or lack of options for a biomarker-defined subgroup. High disease severity alone does not prove that a clinical program can demonstrate benefit.

A strong Carcinoid Tumors, Intestinal strategy connects mechanism to a pre-specified responder population and an endpoint understood by regulators, clinicians, patients and payers. It also tests whether benefit can be measured within a feasible time horizon and whether natural-history variability can be controlled. Patient-reported outcomes, functional measures and health-resource use may add value when standard biomarkers do not capture daily burden.

The recommended first development population is the narrowest segment that remains operationally recruitable and has the clearest biological rationale. Expansion should follow evidence of target engagement and response rather than precede it. This sequencing protects capital and improves the interpretability of early clinical results.

Target mechanism anchor: PTH1R

G protein-coupled receptor for parathyroid hormone (PTH) and for parathyroid hormone-related peptide (PTHLH) (PubMed:10913300, PubMed:18375760, PubMed:19674967, PubMed:27160269, PubMed:30975883, PubMed:35932760, PubMed:8397094). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase (cAMP) (PubMed:30975883, PubMed:35932760). PTH1R is coupled to G(s) G alpha proteins and mediates activation of adenylate cyclase activity (PubMed:20172855, PubMed:30975883, PubMed:35932760). PTHLH dissociates from PTH1R more rapidly than PTH; as consequence, the cAMP response induced by PTHLH decays faster than the response induced by PTH (PubMed:35932760).

The mechanism anchor for this landscape is PTH1R. It is a pathway hypothesis, not an assertion that every patient is target-dependent. Translational diligence should establish tissue expression, human genetic or biomarker support, pharmacologic tractability, target engagement, downstream pathway modulation and a therapeutic window in the intended population.

Critical experiments include orthogonal engagement assays, dose–response work in disease-relevant systems, biomarker qualification, evaluation of compensatory pathways and explicit on-target and off-target safety testing. Human evidence should receive more weight than model-only findings. Negative results in related mechanisms should be analyzed for exposure, population, endpoint and biological lessons.

A go decision requires a chain of evidence: target present in the relevant tissue; modulation achieved at tolerated exposure; pharmacodynamic change observed; and that change plausibly connected to clinical benefit. If any link is missing, the program should remain at a lower investment gate.

Clinical development and competition

The focused query returned 15 registered studies overall. Recent sampled records include:

• NCT07087054 — Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen (CAREFNDR); status Recruiting; phase Phase 3; sponsor Crinetics Pharmaceuticals, Inc.; enrollment 141.
• NCT06876532 — Evaluation of the Inflammation-based Index as a Predictive Marker of Clinical and Radiological Response in Patients Treated With Lu-177 Oxodotreotide for Intestinal Neuroendocrine Tumour (LUTIBI); status Recruiting; phase Not Applicable; sponsor Institut Claudius Regaud; enrollment 150.
• NCT06343428 — Definition of a Multiparametric Prognostic and Predictive System of Classification of NET G3 Patients (TAPIOCA); status Unknown status; phase Not Applicable; sponsor Istituto Europeo di Oncologia Srl; enrollment 20.

Trial count is not equivalent to the number of competing products. Observational studies, natural-history cohorts and multiple trials from one asset can distort the headline. Each record should be normalized by phase, modality, mechanism, sponsor, recruitment status, geography, endpoint and exact disease subtype.

Competitive strategy must compare against the likely standard of care at launch, not only today's treatment. Potential whitespace may come from earlier intervention, genotype selection, improved durability, reduced monitoring, safer chronic use, simpler administration or a rational combination. The differentiation claim should be visible in protocol design and prospectively defined analyses.

Recruitment risk deserves its own workstream in Carcinoid Tumors, Intestinal. Site density, diagnostic testing, competing protocols, travel burden and screen-failure rates should inform country and center selection. Natural-history data can reduce uncertainty but should not substitute for a well-controlled efficacy strategy when endpoints are variable.

Transactions and partnering attractiveness

No directly matched 2023–2026 transaction was returned. This negative signal can mean limited partnering momentum, a broader deal label or asset-level transactions not indexed to the exact indication. Target- and asset-based comparable searches should be added before valuation.

Headline deal value is rarely a clean comparable. Upfront payments, milestones, royalties, options, bundled assets, platform rights and geographic scope must be separated. A defensible comparable set matches indication, target, modality, stage and territory, then explains every remaining difference.

Partner readiness depends on a concise evidence room: disease segmentation, target-validation chain, competitive map, clinical plan, intellectual-property position, chemistry or manufacturability evidence and a transparent risk-adjusted value model. Outreach is most effective around a credible catalyst that can retire a material portion of risk.

For Carcinoid Tumors, Intestinal, direct transaction scarcity can create whitespace, but it can also signal weak validation or a difficult commercial model. Broader pathway deals are useful only when their scientific and economic relevance is made explicit. Avoid treating unrelated rare-disease transactions as interchangeable simply because both populations are small.

Market attractiveness and access

Market attractiveness is shaped by diagnosis infrastructure, specialist concentration, treatment duration, administration setting, payer controls, current alternatives, monitoring burden and geographic reimbursement. A rare population can still be attractive when identification is reliable, centers are concentrated and effect size is meaningful; a larger population can disappoint when diagnosis and access are fragmented.

The commercial model should include conservative, base and upside scenarios. Key variables are diagnosed prevalence, eligible share, launch timing, competing approvals, net price, persistence and achievable penetration. Each assumption should have a source, date and range. Scenario outputs should be updated when new epidemiology, trial or transaction evidence arrives.

Payer research should begin before pivotal design so comparator, endpoint and follow-up choices support reimbursement as well as approval. Evidence plans may need quality-of-life, caregiver burden, hospital use, diagnostic costs or productivity outcomes. The strongest value proposition ties clinical benefit to outcomes that matter across stakeholders.

Risks and decision gates

• Disease-definition risk: confirm a consistently diagnosed and recruitable population.
• Biology risk: demonstrate that PTH1R is relevant in the selected phenotype.
• Translation risk: connect engagement to a biomarker and clinically meaningful endpoint.
• Competition risk: refresh the landscape before every investment gate.
• Operational risk: validate sites, testing capacity and screen-failure assumptions.
• Commercial risk: test access, pricing and adoption with clinicians and payers.
• Data risk: interpret zero-result searches as prompts for broader queries, not proof of absence.

Recommended gates are: confirm population and natural history; validate mechanism in human evidence; define a differentiated target product profile; establish early proof of mechanism; and scale only after clinical signal, operational feasibility and commercial logic converge. Every gate needs pre-agreed stop criteria.

Strategic recommendation

Carcinoid Tumors, Intestinal merits continued, milestone-based evaluation. The opportunity is strongest if a biomarker or phenotype can identify patients with coherent biology, if PTH1R modulation is measurable, and if the proposed benefit is meaningful against future care. The current evidence supports further diligence rather than an unconditional investment decision.

The near-term business-development objective is to build a partner-ready thesis explaining the patient segment, mechanism, competitive whitespace, development path and value-inflection milestones. The scorecard provides a common language for comparison, while the attached evidence and explicit gaps preserve analytical traceability.

Methodology and source note

This report was assembled on August 18, 2026 using Patsnap MCP tools in sequence: disease_fetch, epidemiology_search, target_fetch, clinical_trial_search and drug_deal_search. Results reflect records returned on the access date and may change as databases update. Counts are directional search outputs, not clinical, regulatory or investment advice.

Ranking weights are 40% unmet need, 25% inverse competitive intensity and 35% market attractiveness. Inputs include disease-profile depth, epidemiology coverage, registered-trial activity, development-drug counts and direct recent transaction signals. Before a transaction or portfolio commitment, rerun searches with synonyms, disease roll-ups, gene or pathway names and asset filters.

Conclusion

The central question for Carcinoid Tumors, Intestinal is whether a biologically grounded therapy can produce a material patient benefit in an identifiable population and remain differentiated through launch. The current evidence supplies a structured starting point; the gaps define the next diligence plan. Connected MCP searches make the thesis refreshable as disease knowledge, trials and transactions evolve.